These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25231403)

  • 1. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.
    Song G; Darr DB; Santos CM; Ross M; Valdivia A; Jordan JL; Midkiff BR; Cohen S; Nikolaishvili-Feinberg N; Miller CR; Tarrant TK; Rogers AB; Dudley AC; Perou CM; Zamboni WC
    Clin Cancer Res; 2014 Dec; 20(23):6083-95. PubMed ID: 25231403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.
    Anders CK; Adamo B; Karginova O; Deal AM; Rawal S; Darr D; Schorzman A; Santos C; Bash R; Kafri T; Carey L; Miller CR; Perou CM; Sharpless N; Zamboni WC
    PLoS One; 2013; 8(5):e61359. PubMed ID: 23650496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
    Song G; Tarrant TK; White TF; Barrow DA; Santos CM; Timoshchenko RG; Hanna SK; Ramanathan RK; Lee CR; Bae-Jump VL; Gehrig PA; Zamboni WC
    Nanomedicine; 2015 Oct; 11(7):1797-807. PubMed ID: 26093057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes.
    Andriyanov AV; Koren E; Barenholz Y; Goldberg SN
    PLoS One; 2014; 9(5):e92555. PubMed ID: 24786533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
    Wu SK; Chiang CF; Hsu YH; Lin TH; Liou HC; Fu WM; Lin WL
    Int J Nanomedicine; 2014; 9():4485-94. PubMed ID: 25278753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
    Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
    Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.
    Dumont N; Merrigan S; Turpin J; Lavoie C; Papavasiliou V; Geretti E; Espelin CW; Luus L; Kamoun WS; Ghasemi O; Sahagian GG; Muller WJ; Hendriks BS; Wickham TJ; Drummond DC
    Nanomedicine; 2019 Apr; 17():71-81. PubMed ID: 30654182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
    Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
    BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments.
    Yokoi K; Tanei T; Godin B; van de Ven AL; Hanibuchi M; Matsunoki A; Alexander J; Ferrari M
    Cancer Lett; 2014 Apr; 345(1):48-55. PubMed ID: 24370567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
    Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
    J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.
    Islam MR; Patel J; Back PI; Shmeeda H; Adamsky K; Yang H; Alvarez C; Gabizon AA; La-Beck NM
    Nanotheranostics; 2022; 6(4):451-464. PubMed ID: 36105861
    [No Abstract]   [Full Text] [Related]  

  • 16. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice.
    Wang H; Zheng M; Gao J; Wang J; Zhang Q; Fawcett JP; He Y; Gu J
    Talanta; 2020 Feb; 208():120358. PubMed ID: 31816795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
    Gray BP; McGuire MJ; Brown KC
    PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment.
    Yokoi K; Kojic M; Milosevic M; Tanei T; Ferrari M; Ziemys A
    Cancer Res; 2014 Aug; 74(16):4239-46. PubMed ID: 24853545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
    Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
    Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
    Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
    Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.